Novel Pyridazin-3(2<i>H</i>)-one-based Guanidine derivatives as potential DNA minor groove binders with anticancer activity
Loading...
Identifiers
Publication date
Advisors
Tutors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
ACS Publications
Abstract
Novel aryl guanidinium analogues containing the pyridazin-3(2H)-one core were proposed as minor groove binders (MGBs) with the support of molecular docking studies. The target dicationic or monocationic compounds, which show the guanidium group at different positions of the pyridazinone moiety, were synthesized using the corresponding silyl-protected pyridazinones as key intermediates. Pyridazinone scaffolds were converted into the adequate bromoalkyl derivatives, which by reaction with N,N’-di-Boc-protected guanidine followed by acid hydrolysis provided the hydrochloride salts 1–14 in good yields. The ability of new pyridazin-3(2H)-one-based guanidines as DNA binders was studied by means of DNA UV-thermal denaturation experiments. Their antiproliferative activity was also explored in three cancer cell lines (NCI-H460, A2780, and MCF-7). Compounds 1–4 with a bis-guanidinium structure display a weak DNA binding affinity and exhibit a reasonable cellular viability inhibition percentage in the three cancer cell lines studied
Description
Bibliographic citation
María Carmen Costas-Lago, Noemí Vila, Adeyemi Rahman, Pedro Besada, Isabel Rozas, José Brea, María Isabel Loza, Elisa González-Romero, and Carmen Terán ACS Medicinal Chemistry Letters 2022 13 (3), 463-469 DOI: 10.1021/acsmedchemlett.1c00633
Relation
Has part
Has version
Is based on
Is part of
Is referenced by
Is version of
Requires
Publisher version
https://doi.org/10.1021/acsmedchemlett.1c00633Sponsors
This research was supported with funding from Universidade de Vigo, Irish Research Council (IRC-GOIPG/2017/956), “ERDF A way of making Europe”, and the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21)
Rights
© 2022 The Authors. Published by American Chemical Society. This publication is licensed under CC-BY 4.0
Attribution 4.0 International
Attribution 4.0 International







